Ocean Biomedical (NASDAQ: OCEA) is proud to announce a major breakthrough in cancer immunotherapy! Its Scientific Co-founder, Dr. Jack A. Elias, MD, has recently been granted a patent for a therapy that can reverse immune system suppression through the binding of chitinase 3-like-1 (CHi3L1) polypeptides with the company’s own immunoglobulin antibody. Research has proven the efficacy of this process in suppressing primary and metastatic tumor growth in animal models, providing hope for the treatment of various forms of abdominal cancer.
Ocean Biomedical’s groundbreaking monoclonal antibody has been granted a patent with the potential to revolutionize the oncology field. By suppressing CHi3L1, this innovative platform will activate natural anticancer immune responses in a broad range of cancers. Such cancers include prostate, colon and rectal cancer, ovarian cancer, breast cancer, kidney cancer, glioblastoma, melanoma, and lung cancer.
Moreover, the newly granted patent claims cover the composition of the monoclonal antibodies targeting and inhibiting the CHi3L1. With this technology, the possibilities for oncology treatments are seemingly limitless.
Dr. Elias has made an incredible breakthrough discovery, uncovering an entirely novel approach to the control of cancer. By controlling the protein CHi3L1, it is now possible to control multiple cancer pathways at once. This discovery is groundbreaking and entirely new, as it has the potential to dramatically shape cancer research, treatment, and patient outcomes in the years to come.
We are thrilled that Dr. Elias’ work has been granted this invaluable patent, and we are actively pursuing the necessary steps to bring the anti-CHi3L1 antibodies to the clinic for potential use as groundbreaking cancer treatments. At Ocean Biomedical, we are committed to utilizing the latest advances in science to create revolutionary therapeutics that could change the course of medicine.
The incredible findings from Ocean Biomedical’s research could save thousands of lives, not only from lung metastasis and melanoma, but also from glioblastoma and other forms of cancer. According to Dr. Chirinjeev Kathuria, co-founder and Executive Chairman of the biomedical firm, these breakthroughs have the potential to be a game-changer in the fight against diseases.
Dr. Jack A. Elias is a renowned pulmonary care specialist and research pioneer, widely recognized for his work as former Chair of Yale’s Department of Internal Medicine, Dean Emeritus of Medicine and Biological Sciences at Brown University, and current Professor of Translational Science, Medicine and Molecular Microbiology and Immunology at The Warren Alpert Medical School of Brown University.
In 2019, he co-founded Ocean Biomedical with Brown University colleagues, alums, and experienced pharma business leaders, committed to tackling major unmet medical needs and bringing more discovery science to medical therapeutics.
About Cancer Immunotherapy
Immunotherapy is an innovative way of treating cancer that revs up the body’s natural immune system to take action against tumor growth and cancer cells. Ocean Biomedical researches and develops monoclonal antibodies (immune system proteins) to target a polypeptide associated with cancer growth in any number of cancers.
By suppressing this polypeptide (CHi3L1), Ocean Biomedical has found success in suppressing primary and metastatic tumor growth in multiple animal models. This new patent reflects the potential for the immunotherapy’s use in various forms of visceral cancer.
About Ocean Biomedical
Ocean Biomedical, based in Providence, Rhode Island, is on a groundbreaking journey to revolutionize healthcare and save lives. With an innovative model that accelerates the commercialization of discoveries from research universities and medical centers, the company is making breakthroughs in the fields of lung cancer, brain cancer, pulmonary fibrosis, and malaria prevention and treatment.
Committed to solving some of the world’s most complex issues, Ocean Biomedical is pushing the boundaries of biopharmaceutical innovation and bringing life-changing solutions to those who need them most.
Forward-Looking Statements
At Ocean Biomedical, Inc., we believe that having forward-looking statements is essential to having a successful business. We’re making predictions regarding our initial product candidates and the timing of IND-enabling studies, the future addition of assets to our pipeline, the potential benefits of our product candidates, our future financial condition, and our plans for future strategy and operations.
We also compare ourselves to other industry trends and competitors. All these predictions are based on careful consideration and our current expectations of management. They are provided to give you, the investor, a better understanding of the great possibilities and potential of our company – and although they may not be certain, they offer invaluable insight into our future.
Unfortunately, the exciting discoveries announced by the Company are still on shaky ground, as they have only been tested by laboratory and animal studies thus far. No studies have provided evidence of similar safety or effectiveness in humans, so the true potential for any of the Company’s treatments may be years away – only after clinical trials and eventual FDA approval will we know whether their treatments will achieve the potential benefits speculated upon.
The future is full of possibilities that can be influenced by events of today. That’s why, at the Company, we look ahead with cautious optimism. We cannot guarantee what the future holds, but we strive to make informed decisions and assessments that mitigate the risks associated with these unknowns. To that end, we require all stakeholders to review our Form 10-K for the year ending December 31, 2022, along with any other documents filed with the SEC.
These filings highlight the various risks posed to the Company, as well as strategies to address them. However, forward-looking statements should only be viewed in the context of the date they are made, and no guarantees of future performance can be made. We are open to new perspectives that will help us shape our decisions towards a better future.